Transcription factor IIIA is a protein that in humans is encoded by the GTF3Agene.[1][2] It was first isolated and characterized by Wolffe and Brown in 1988.
References
↑ Arakawa H, Nagase H, Hayashi N, Ogawa M, Nagata M, Fujiwara T, Takahashi E, Shin S, Nakamura Y (Jul 1995). "Molecular cloning, characterization, and chromosomal mapping of a novel human gene (GTF3A) that is highly homologous to Xenopus transcription factor IIIA". Cytogenetics and Cell Genetics. 70 (3–4): 235–8. doi:10.1159/000134041. PMID7789179.
Murphy JE, Keen JH (May 1992). "Recognition sites for clathrin-associated proteins AP-2 and AP-3 on clathrin triskelia". The Journal of Biological Chemistry. 267 (15): 10850–5. PMID1587861.
Seifart KH, Wang L, Waldschmidt R, Jahn D, Wingender E (Jan 1989). "Purification of human transcription factor IIIA and its interaction with a chemically synthesized gene encoding human 5 S rRNA". The Journal of Biological Chemistry. 264 (3): 1702–9. PMID2912980.
Drew PD, Nagle JW, Canning RD, Ozato K, Biddison WE, Becker KG (Jul 1995). "Cloning and expression analysis of a human cDNA homologous to Xenopus TFIIIA". Gene. 159 (2): 215–8. doi:10.1016/0378-1119(95)00145-V. PMID7622052.
Moorefield B, Roeder RG (Aug 1994). "Purification and characterization of human transcription factor IIIA". The Journal of Biological Chemistry. 269 (33): 20857–65. PMID8063702.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (Nov 2004). "Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis". Clinical Cancer Research. 10 (22): 7621–8. doi:10.1158/1078-0432.CCR-04-1061. PMID15569994.
Yamashita A, Takada T, Nemoto K, Yamamoto G, Torii R (Jul 2006). "Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage". FEBS Letters. 580 (17): 4121–5. doi:10.1016/j.febslet.2006.06.057. PMID16828750.
Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L, Bar-Eli M (Jun 2007). "Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo". Oncogene. 26 (28): 4049–58. doi:10.1038/sj.onc.1210193. PMID17224907.